Moleculin Biotech's Annamycin Cardiac Safety Data Accepted for ASCO Presentation

summarizeSummary

Moleculin Biotech announced that strong cardiac safety data for its lead drug candidate, Annamycin, has been accepted for presentation at the upcoming ASCO Annual Meeting, reinforcing its potential as a safer anthracycline.

check_boxKey Events

• ASCO Abstract Acceptance

  An abstract featuring pooled cardiac safety data for Annamycin has been accepted for poster presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29 – June 2, 2026).

• Strong Cardiac Safety Profile

  Pooled analysis from 90 patients across five trials showed no statistically significant change in Left Ventricular Ejection Fraction (LVEF) and no evidence of drug-induced cardiotoxicity, even at cumulative doses exceeding conventional lifetime anthracycline limits.

• Addresses Key Treatment Barrier

  This data supports Annamycin's potential to provide effective anthracycline therapy without the traditional cumulative dose limitations associated with cardiotoxicity, a major issue for existing chemotherapies.

• Supports Pivotal Trial

  The positive safety findings further strengthen the rationale for the company's ongoing pivotal Phase 2b/3 MIRACLE trial in patients with relapsed or refractory acute myeloid leukemia (AML).

auto_awesomeAnalysis

This filing announces the acceptance of strong cardiac safety data for Annamycin, Moleculin Biotech's lead drug candidate, for presentation at the prestigious ASCO Annual Meeting. The data, showing no significant cardiotoxicity even at high cumulative doses, is critical because cardiotoxicity is a major limiting factor for conventional anthracycline chemotherapy. For a company facing a 'going concern' warning and needing significant capital, this positive clinical validation for its pivotal Phase 2b/3 trial strengthens the investment thesis and could be crucial for future financing efforts.